PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples